FOLLOWUS
1. Department of Integrated Traditional Chinese Medicine and Western Medicine, Beijing Youan Hospital Affiliated to Capital Medical University,Beijing,China
2. Department of Communicable Diseases, Children’s Hospital of Hunan Province,Changsha,China
3. Department of Pediatrics, Guangzhou Medical Center for Women and Children,Guangzhou,China
4. Department of Pediatrics, First Hospital Affiliated to Guangxi Medical University,Nanning,China
5. Department of Internal Medicine, Handan Maternal and Child Health Hospital,Hebei Province,Handan,China
6. Department of Internal Medicine, Children’s Hospital of Jiangxi Province,Nanchang,China
7. Department of Pediatrics, The People’s Hospital of Liuzhou,Guangxi Province,Liuzhou,China
8. Center for Drug Clinical Research, Shanghai University of Chinese Medicine,Shanghai,China
9. Medical Research Center, Beijing Chaoyang Hospital, Capital Medical University,Beijing,China
10. Department of Pediatrics, Kaifeng Children’s Hospital,Henan Province,Kaifeng,China
纸质出版日期:2017,
网络出版日期:2016-7-9,
Scan for full text
Li, Xh., Li, Sj., Xu, Y. et al. Effect of integrated Chinese and Western medicine therapy on severe hand, foot and mouth disease: A prospective, randomized, controlled trial., Chin. J. Integr. Med. 23, 887–892 (2017). https://doi.org/10.1007/s11655-016-2504-3
Xiu-hui Li, Shuang-jie Li, Yi Xu, et al. Effect of integrated Chinese and Western medicine therapy on severe hand, foot and mouth disease: A prospective, randomized, controlled trial[J]. Chinese Journal of Integrative Medicine, 2017,23(12):887-892.
Li, Xh., Li, Sj., Xu, Y. et al. Effect of integrated Chinese and Western medicine therapy on severe hand, foot and mouth disease: A prospective, randomized, controlled trial., Chin. J. Integr. Med. 23, 887–892 (2017). https://doi.org/10.1007/s11655-016-2504-3 DOI:
Xiu-hui Li, Shuang-jie Li, Yi Xu, et al. Effect of integrated Chinese and Western medicine therapy on severe hand, foot and mouth disease: A prospective, randomized, controlled trial[J]. Chinese Journal of Integrative Medicine, 2017,23(12):887-892. DOI: 10.1007/s11655-016-2504-3.
To evaluate the efficacy and safety of Chinese medicine (CM) plus Western medicine (WM) in the treatment of pediatric patients with severe hand
foot and mouth disease (HFMD) by conducting a prospective
controlled
and randomized trial. A total of 451 pediatric patients with severe HFMD were randomly assigned to receive WM therapy alone (224 cases
WM therapy group) or CM [Reduning Injection (热 毒宁注射液) or Xiyanping Injection (喜炎平注射液)] plus WM therapy (227 cases
CM plus WM therapy group) for 7–10 days
according to a web-based randomization system. The primary outcome was fever clearance time
which was presented as temperature decreased half-life time. The secondary outcomes included the rate of rash/herpes disappearance within 120 h
as well as the rate for cough
runny nose
lethargy and weakness
agitation or irritability
and vomiting clearance within 120 h. The drug-related adverse events were also recorded. The temperature decreased half-life time was 40.4 h in the WM therapy group
significantly longer than 27.2 h in the CM plus WM therapy group (P<0.01). Moreover
the rate for rash/herpes disappearance within 120 h was 43.6% (99/227) in the CM plus WM therapy group
significantly higher than 29.5% (66/224) in the WM therapy group (P<0.01). In addition
the rate for cough
lethargy and weakness
agitation or irritability disappearance within 120 h was 32.6% (74/227) in the CM plus WM therapy group
significantly higher than 19.2% (43/224) in the WM therapy group (P<0.01). No drug-related adverse events were observed during the course of the study. The combined CM and WM therapy achieved a better therapeutic efficacy in treating severe HFMD than the WM therapy alone. Reduning or Xiyanping Injections may become an important complementary therapy to WM for relieving the symptoms of severe HFMD. (Registration No. NCT01145664)
To evaluate the efficacy and safety of Chinese medicine (CM) plus Western medicine (WM) in the treatment of pediatric patients with severe hand
foot and mouth disease (HFMD) by conducting a prospective
controlled
and randomized trial. A total of 451 pediatric patients with severe HFMD were randomly assigned to receive WM therapy alone (224 cases
WM therapy group) or CM [Reduning Injection (热 毒宁注射液) or Xiyanping Injection (喜炎平注射液)] plus WM therapy (227 cases
CM plus WM therapy group) for 7–10 days
according to a web-based randomization system. The primary outcome was fever clearance time
which was presented as temperature decreased half-life time. The secondary outcomes included the rate of rash/herpes disappearance within 120 h
as well as the rate for cough
runny nose
lethargy and weakness
agitation or irritability
and vomiting clearance within 120 h. The drug-related adverse events were also recorded. The temperature decreased half-life time was 40.4 h in the WM therapy group
significantly longer than 27.2 h in the CM plus WM therapy group (P<0.01). Moreover
the rate for rash/herpes disappearance within 120 h was 43.6% (99/227) in the CM plus WM therapy group
significantly higher than 29.5% (66/224) in the WM therapy group (P<0.01). In addition
the rate for cough
lethargy and weakness
agitation or irritability disappearance within 120 h was 32.6% (74/227) in the CM plus WM therapy group
significantly higher than 19.2% (43/224) in the WM therapy group (P<0.01). No drug-related adverse events were observed during the course of the study. The combined CM and WM therapy achieved a better therapeutic efficacy in treating severe HFMD than the WM therapy alone. Reduning or Xiyanping Injections may become an important complementary therapy to WM for relieving the symptoms of severe HFMD. (Registration No. NCT01145664)
handfoot and mouth diseaseReduning InjectionXiyanping InjectionChinese Medicine
handfoot and mouth diseaseReduning InjectionXiyanping InjectionChinese Medicine
Fan X, Jiang J, Liu Y, Huang X, Wang P, Liu L, et al. Detection of human enterovirus 71 and coxsackievirus A16 in an outbreak of hand, foot, and mouth disease in Henan Province, China in 2009. Virus Genes 2013;46:1–9.
Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010;14:e1076-e101081.
Zhu J, Luo Z, Wang J, Xu Z, Chen H, Fan D, et al. Phylogenetic analysis of enterovirus 71 circulating in Beijing, China from 2007 to 2009. PloS One 2013;8:e56318.
Zhang J, Sun J, Chang Z, Zhang W, Wang Z, Feng Z. Characterization of hand, foot, and mouth disease in China between 2008 and 2009. Biomed Environ Sci 2011;24:214–221.
Zhou H, Guo S, Zhou H, Zhu Y, Zhang L, Zhang W. Clinical characteristics of hand, foot and mouth disease in Harbin and the prediction of severe cases. Chin Med J 2012;125:1261–1265.
Zhu Q, Hao Y, Ma J, Yu S, Wang Y. Surveillance of hand, foot, and mouth disease in mainland China (2008–2009). Biomed Environ Sci 2011;24:349–356.
National Health and Family Planning Commission of the People's Republic of China. Report of epidemic situation of infectious disease in China from January of 2010 to January of 2011. Available at http://www.moh.gov.cn/publicfiles/ business/htmlfiles/mohjbyfkzj/s3578/201102/50646.htm.
Tian H, Yang QZ, Liang J, Dong SY, Liu ZJ, Wang LX. Clinical features and management outcomes of severe hand, foot and mouth disease. Med Princ Pract 2012;21:355–359.
National Health and Family Planning Commission of the People's Republic of China. Guideline for the diagnosis and treatment of hand foot and mouth disease, Beijing, China, 2010. Available at http://www.nhfpc.gov.cn/mohyzs/ s3586/201004/46884.shtml
Xue B, Yao Z, Yu R. Studies on anti-EV71 virus activity of traditional Chinese medicine and its clinical application in treatment of HFMD. China J Chin Mater Med (Chin) 2011;36:3366–3370.
Lin TY, Liu YC, Jheng JR, Tsai HP, Jan JT, Wong WR, et al. Anti-enterovirus 71 activity screening of Chinese herbs with anti-infection and inflammation activities. Am J Chin Med 2009;37:143–158.
Mu Y, Chen X, Zhang A. Effect of Reduning Injection on HFMD in children: a randomized controlled trial. Chin J Integr Tradit West Med (Chin) 2011;31:1209–1212.
Li X, Zhang C, Shi Q, Yang T, Zhu Q, Tian Y, et al. Improving the efficacy of conventional therapy by adding andrographolide sulfonate in the treatment of severe hand, foot, and mouth disease: a randomized controlled trial. Evid Based Complement Alternat Med 2013;2013:316250.
Cao H, Liu Z, Steinmann P, Mu Y, Luo H, Liu J. Chinese herbal medicines for treatment of hand, foot and mouth disease: a systematic review of randomized clinical trials. Eur J Integr Med 2012;4:e85-e111.
Pharmacopoeia Committee of People's Republic of China. Chinese pharmacopoeia. Beijing: Chemical Industry Press;2005.
Wang C, Cao B, Liu QQ, Zou ZQ, Liang ZA, Gu L, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med 2011;155:217–225.
Zu M, Zhou D, Gao L, Liu A, Du G. Evaluation of Chinese traditional patent medicines against influenza virus in vitro. Acta Pharmaceut Sinica (Chin) 2010;45:408–412.
Lu C, Liu X, Ding X, Chen X, Fan H, Liu Y, et al. A metabolomics profiling study in hand-foot-and-mouth disease and modulated pathways of clinical intervention using liquid chromatography/quadrupole time-of-flight mass spectrometry. Evid Based Complement Alternat Med 2013;2013:647452.
0
浏览量
0
Downloads
2
CSCD
关联资源
相关文章
相关作者
相关机构